Investment opportunity
Invest in the future of affordable fertility care
We are building the affordability layer of fertility care in APAC. Backed by HKSTP and led by a team with deep MedTech and clinical expertise.
Current raise
Pre-Seed Round — USD 400,000 · 10% Equity
Pre-money valuation $3.6M | Post-money $4.0M
Market opportunity
$16B APAC market by 2033
Growing at 10.9% CAGR, with 75% unmet demand and strong demographic urgency across Southeast Asia.
Proven technology
IVC: designed for resource‑limited settings
Decades of clinical research. IVC requires minimal lab infrastructure, scales easily, and published data suggest outcomes comparable to traditional IVF.
Scalable model
High margins, asset‑light expansion
Device sales, Greenfield centres, and clinical partnerships. Built for rapid scale across APAC.
Use of funds
Where the $400k goes
~$130k
Clinical trial
Local pilot study at Malaysian teaching hospital
~$90k
Manufacturing
Tooling & pilot batch with ISO 13485 partner (LOI signed)
~$80k
Regulatory
MDA Class B submission & approval
~$100k
Operations
Team, runway, and buffer for 12–18 months
EVEA is in development, with an ISO 13485 manufacturing partner based in Shenzhen, China (LOI signed), and a clinical trial planned for 2026–2027.
Traction
Key milestones — already achieved
Clinical
- Clinical trial LOI with a Malaysian teaching hospital
- Pilot site LOI with a fertility hospital in Vietnam
- Co‑founder led the first intravaginal culture birth in Southeast Asia (peer‑reviewed)
Manufacturing & IP
- ISO 13485 manufacturing partner (Shenzhen, China) – LOI signed
- Patent application filed (Hong Kong, March 2026)
- FTO opinion received for Malaysia
Strategic
- MOU with a US‑based IVF training academy
- Training pipeline for APAC embryologists
Regulatory
- MDA Class B — re‑use pathway confirmed
- Target approval Q4 2027 (6–9 months)
Full investor deck
Request the full package
Financials & milestones available on request under NDA. Please use the form below – we’ll respond within 48 hours.
The information on this page is provided for informational purposes only and does not constitute an offer to sell securities. Any investment decisions should be made only after reviewing full documentation and consulting with professional advisors.
